Table 3. Estimates of exploration and resection percentages after neoadjuvant treatment and restaging, and estimates of patients with complete response/partial response, stable disease, and progressive disease including the 95% confidence interval from the random effect model and number of assessable studies for each group (n).

Group	Complete Response	Partial Response	Stable Disease	Progressive Disease	Explored/All	Resected/All	R0/Resected	Resected/Explored
All patients	3.9%[3.0%–4.9%]I2 = 44.7%[28.1%–57.5%](n = 82)	29.1%[24.5%–34.0%]I2 = 86.9%[84.2%–89.1%](n = 75)	43.9%[37.9%–50.0%]I2 = 87.7%[85%–89.9%](n = 63)	20.8%[17.3%–24.6%]I2 = 81.4%[77.3%–84.8%](n = 78)	69.5%[62.1%–76.4%]I2 = 95.5%[94.9%–96%](n = 88)	50.7%[44.0%–57.4%]I2 = 95.2%[94.6%–95.7%](n = 111)	79.6%[74.8%–83.9%]I2 = 81.3%[77.4%–84.6%](n = 86)	77.9%[72.4%–82.9%]I2 = 89%[87%–90.6%](n = 88)
Tumor resectable before treatment (group 1)	3.6%[2.0%–5.5%]I2 = 53.9%[29.3%–70%](n = 28)	30.6%[20.7%–41.4%]I2 = 90.3%[86.7%–92.9%](n = 23)	42.1%[30.5%–54.1%]I2 = 91.4%[88.4%–93.6%](n = 23)	20.9%[16.9%–25.3%]I2 = 66.9%[51.2%–77.5%](n = 29)	88.1%[82.9%–92.4%]I2 = 86.2%[81.5%–89.7%](n = 32)	73.6%[65.9%–80.6%]I2 = 90.1%[87.3%–92.3%](n = 35)	82.1%[73.1%–89.6%]I2 = 89.3%[85.5%–92%](n = 26)	85.7%[78.9%–91.2%]I2 = 88.6%[85%–91.4%](n = 32)
Tumor non-resectable before treatment (group 2)	4.8%[3.5%–6.4%]I2 = 33.9%[3.4%–54.8%](n = 42)	30.2%[24.5%–36.3%]I2 = 81.8%[75.9%–86.2%](n = 40)	41.6%[34.6%–48.7%]I2 = 75%[64.2%–82.6%](n = 29)	20.8%[14.5%–27.8%]I2 = 85.4%[80.7%–88.9%](n = 36)	46.9%[36.9%–57.1%]I2 = 93.7%[92.2%–94.8%](n = 41)	33.2%[25.8%–41.1%]I2 = 92.5%[91%–93.7%](n = 57)	79.2%[72.4%–85.2%]I2 = 70.2%[59.7%–78%](n = 45)	69.9%[61.2%–77.9%]I2 = 79.9%[73.3%–84.9%](n = 41)